Recombinant Human TP53

• Cat.No.: TP53-30262TH
• Product Overview: p53 Mutant Human Recombinant full length protein shows a 81 kDa band on SDS-PAGE.

Specification

• Description: This gene encodes tumor protein p53, which responds to diverse cellular stresses to regulate target genes that induce cell cycle arrest, apoptosis, senescence, DNA repair, or changes in metabolism. p53 protein is expressed at low level in normal cells and at a high level in a variety of transformed cell lines, where its believed to contribute to transformation and malignancy. p53 is a DNA-binding protein containing transcription activation, DNA-binding, and oligomerization domains. It is postulated to bind to a p53-binding site and activate expression of downstream genes that inhibit growth and/or invasion, and thus function as a tumor suppressor. Mutants of p53 that frequently occur in a number of different human cancers fail to bind the consensus DNA binding site, and hence cause the loss of tumor suppressor activity. Alterations of this gene occur not only as somatic mutations in human malignancies, but also as germline mutations in some cancer-prone families with Li-Fraumeni syndrome. Multiple p53 variants due to alternative promoters and multiple alternative splicing have been found. These variants encode distinct isoforms, which can regulate p53 transcriptional activity.
• Source: E. coli
• Form: Liquid
• Storage buffer: Preservative: NoneConstituents: 20% Glycerol, 50mM Tris acetate, 1mM EDTA, pH 7.5
• Storage: Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.

Gene Information

• Gene Name: TP53 tumor protein p53 [ Homo sapiens ]
• Official Symbol: TP53
• Synonyms: TP53; tumor protein p53; cellular tumor antigen p53; LFS1; Li Fraumeni syndrome; p53
• Gene ID: 7157
• mRNA Refseq: NM_000546
• Protein Refseq: NP_000537
• MIM: 191170
• Uniprot ID: P04637
• Chromosome Location: 17p13.1
• Pathway: Activation of BH3-only proteins, organism-specific biosystem; Activation of NOXA and translocation to mitochondria, organism-specific biosystem; Activation of PUMA and translocation to mitochondria, organism-specific biosystem; Amyotrophic lateral sclerosis (ALS), organism-specific biosystem; Amyotrophic lateral sclerosis (ALS), conserved biosystem
• Function: ATP binding; DNA binding; DNA strand annealing activity; MDM2 binding; RNA polymerase II transcription factor binding

Reviews

02/26/2023

By actively engaging with researchers and understanding their needs, manufacturers can contribute significantly to the success and impact of research involving the TP53 protein.

11/05/2020

This flexibility allows for tailored approaches and provides researchers with more options to study specific aspects of TP53 biology or its interactions with other molecules.

07/24/2017

Manufacturers can provide comprehensive product information, including data on the functionality, stability, and handling of TP53 protein.

Q&As

Can TP53 status be used for cancer risk assessment and screening in individuals with a family history of cancer?

Yes, identifying TP53 mutations in families with a history of early-onset cancers can help identify individuals at high risk for cancer and guide screening and prevention strategies.

What are the challenges in developing targeted therapies for TP53-mutated cancers?

TP53 mutations are highly diverse, making it challenging to develop a one-size-fits-all therapy. Additionally, the p53 pathway is complex, and disrupting it can have unintended consequences.

Can TP53 status influence eligibility for certain clinical trials?

Yes, TP53 mutation status can be a criterion for eligibility in specific clinical trials, especially those testing experimental treatments that may target the p53 pathway.

How might TP53 status affect decisions regarding surgery, chemotherapy, and radiation therapy?

TP53 status can influence treatment decisions. For example, patients with TP53 mutations may require more aggressive treatment approaches or different chemotherapy regimens.

Are there targeted therapies specifically designed for TP53-mutated cancers?

Currently, there are no specific targeted therapies approved solely for TP53-mutated cancers. However, research is ongoing to develop drugs that target the altered p53 pathway.